Administration and handling of cell product Management of Adverse Events Patient card

Find attached the article ''To Transplant or Not To Transplant in First Remission Acute Lymphoblastic Leukemia? Study group data give some answers, but not all.'' authored by Prof. Spyridonidis and published at American Society for Transplantation and Cellular Therapy

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 40 mins Historically, Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been associated with poor outcomes, and allogeneic hematopoietic cell transplantation (alloHCT) is recommended in first complete remission (CR1). However, in the...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 35 mins With the introduction of large-scale molecular profiling methods and high-throughput sequencing technologies, the genomic features of most lymphoid neoplasms have been characterized at an unprecedented scale. Although the principles for...

Post-transplant Cyclophosphamide in Acute Leukemia Patients Receiving more than 5/10 HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation from Related Donors: a Study on behalf of the ALWP of the EBMT Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Valera, Dr Tsokanas, A. Christopoulou Duration: 40 mins

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Valera, Dr Tsokanas, A. Christopoulou, E. Sagiadinou Duration: 40 mins Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

Find attached the slides of PeerVoice seminar, presented by Prof Mohty  Participants: Prof. Spyridonidis, Dr Liga, Dr Tsokanas, Dr Valera. Duration: 40 mins

Presenter: Prof. Spyridonidis Participants:Dr Liga, Dr Valera, Dr Tsokanas Duration: 40 mins These Guidelines were developed by the European Hematology Association (EHA) and European Society for Medical Oncology (ESMO). The 2 societies nominated authors to write the guidelines as well as reviewers to...

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Valera, Dr Tsokanas 

Find attached the presentation of Prof. Spyridonidis at 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) that was held on Berlin, 27-30 October 2022

Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Valera, Dr. Tsokanas Duration: 20mins Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hemato- logic malignancies. Two CAR T products were recently approved in the United States...

https://doi.org/10.1182/blood.2021013290 Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 45 min Patients with B-lineage acute lymphoblastic leukemia (ALL) are at high-risk for relapse after allogeneic hematopoietic cell transplantation (HCT). We conducted a single-center phase 2 study evaluating the feasibility of 4...

Presenter: Dr Liga Participants: Prof. Spyridonidis, Dr Tsokanas, A. Christopoulou, Dr Valera Duration: 40 mins

Επισυνάπτεται η παρουσίαση του Καθ. Αλέξανδρου Σπυριδωνίδη στην επιστημονική διημερίδα του ΕΟΜ με τίτλο «Βελτιώνοντας τις διαδικασίες και την ποιότητα των μεταμοσχεύσεων στην Ελλάδα», η οποία πραγματοποιήθηκε στις 14 & 15 Οκτωβρίου 2022 στο Μουσείο Μπενάκη Παρουσίαση: Kαθ. Αλέξανδρος Σπυριδωνίδης Συμμετέχοντες: Δρ Λίγκα...

Presenter: Prof Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Valera Duration: 40 mins https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00223-X/fulltext?dgcid=hubspot_update_feature_updates22_lanhae&utm_campaign=update-lanhae&utm_medium=email&_hsmi=229262662&_hsenc=p2ANqtz-_4qThtytktyouVD9PQP8m6s2Fw61Pl4L4GAD65juL7jMS0i30Ms-ENPUL-k5yafQMCP8p8BUvXYXbK66-tdjlqjUP42w&utm_content=229205353&utm_source=hs_email The effect of the gut microbiota on patients’ outcomes after allogeneic haematopoietic cell transplantation (HCT) is now well established. In particular, gut microbiota dysbiosis has been associated with acute graft-versus-host...

Presenter: Prof. Alexandros Spyridonidis 2022_AML_NGS_EAE_.pptx

Background- Therapies beyond hypomethylating agents such as azacitidine are needed in high-risk myelodysplastic syndromes. Venetoclax is an orally bioavailable small molecule BCL-2 inhibitor that is synergistic with hypomethylating agents. We therefore aimed to evaluate the safety, tolerability, and preliminary activity...